Previous Treatment in Main Study | |||
---|---|---|---|
Total Group | Ovaleap® | Gonal-f® | |
Cycle 2 | N = 146 | N = 80 | N = 66 |
Oocyte quality, n (%) oocytes | |||
Z1 (Best) | 162 (18.4) | 87 (17.6) | 75 (19.3) |
Z2 | 363 (41.2) | 210 (42.6) | 153 (39.4) |
Z3 | 234 (26.6) | 129 (26.2) | 105 (27.1) |
Z4 (Worst) | 122 (13.8) | 67 (13.6) | 55 (14.2) |
Total 2 PN oocytes | 881 (100.0) | 493 (100.0) | 388 (100.0) |
Cycle 3 | N = 60 | N = 33 | N = 27 |
Oocyte quality, n (%) oocytes | |||
Z1 (Best) | 71 (17.4) | 34 (15.7) | 37 (19.5) |
Z2 | 160 (39.3) | 84 (38.7) | 76 (40.0) |
Z3 | 127 (31.2) | 68 (31.3) | 59 (31.1) |
Z4 (Worst) | 49 (12.0) | 31 (14.3) | 18 (9.5) |
Total 2 PN oocytes | 407 (100.0) | 217 (100.0) | 190 (100.0) |